European Archives of Oto-Rhino-Laryngology

, Volume 276, Issue 3, pp 761–765 | Cite as

Effects of montelukast on human nasal mucosa

  • Hsing-Won Wang
  • Jih-Chin Lee
  • Pei-Chuan Wu
  • Yueng-Hsiang Chu
  • Yuan-Yung Lin
  • Li-Hsiang ChengEmail author



Montelukast is a selective and orally active leukotriene D4 receptor antagonist often used in treating asthma and allergic rhinitis. Montelukast nasal spray was developed to avoid systemic adverse effects of the drug in vitro. However, the effects of montelukast on human nasal mucosa are not yet fully explored and potential nasal vascular side effects of the drug merit further exploration. First, the effects of montelukast on vasocontractile responses generated by smooth muscles in the vascular structures of human nasal mucosa were investigated directly in vitro.


This study examined the effects of montelukast on human nasal mucosa in terms of mucosa resting tension, vasoconstriction caused by 10− 6 M methoxamine as a sympathetic mimetic, and electrically induced vasoconstrictions.


The results indicated that addition of methoxamine to the incubation medium caused the nasal mucosa to vasocontract in a dose-dependent manner. Addition of montelukast at doses of 10− 5 M or above elicited a significant vasodilation response to 10− 6 M methoxamine-induced vasoconstriction. Montelukast could not inhibit electrical field stimulation-induced spike vasoconstriction. Moreover, increase in concentration of montelukast had minimal effect on basal tension of nasal mucosa.


The study indicated significant vasodilation on human nasal mucosa under high concentrations of montelukast with a probable α-adrenoceptor antagonism. Hence, the nasal activity of α-adrenergic agonist nasal spray for nasal obstruction may be reduced in those using concomitant (oral or local spray) montelukast.


Montelukast Sympathetic function Human nasal mucosa 



No source of financial support or funding.

Compliance with ethical standards

Conflict of interest

Authors declare that they have no conflict of interest.

Ethical approval

The study was approved by the institutional review board of the Tri-Service General Hospital. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study, and each patient had given a written informed consent about the use of the samples for medical research.


  1. 1.
    Cingi C, Muluk NB, Ipci K, Sahin E (2015) Antileukotrienes in upper airway inflammatory diseases. Curr Allergy Asthma Rep 15:64CrossRefPubMedGoogle Scholar
  2. 2.
    Jones TR, Labelle M, Belley M, Champion E, Charette L et al (1995) Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist. Can J Phsiol Pharmacol 73:191–201CrossRefGoogle Scholar
  3. 3.
    Joachim RA, Quarcoo D, Arck PC, Herz U, Renz H et al (2003) Stress enhances airway reactivity and airway inflammation in an animal model of allergic bronchial asthma. Psychosom Med 65:811–815CrossRefPubMedGoogle Scholar
  4. 4.
    Perry TT, Corren J, Philip G, Kim EH, Conover-Walker MK et al (2004) Protective effect of montelukast on lower and upper respiratory tract responses to short-term cat allergen exposure. Ann Allergy Asthma Immunol 93:431–438CrossRefPubMedGoogle Scholar
  5. 5.
    Papadopoulous NG, Philip G, Giezek H, Watkins M, Smugar SS et al (2009) The efficacy of montelukast during the allergy season in pediatric patients with persistent asthma and seasonal aeroallergen sensitivity. J Asthma 46:413–420CrossRefGoogle Scholar
  6. 6.
    Philip G, Nayak AS, Berger WE (2004) The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr Med Res Opin 20:1549–1558CrossRefPubMedGoogle Scholar
  7. 7.
    Tuggey JM, Hosker HS (2000) Churg-Strauss syndrome associated with montelukast therapy. Thorax 55:805–806CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Aypak C, Turedi O, Solmaz N, Yikilkan H, Gorpelioglu (2013) A rare adverse effect of montelukast treatment: ecchymosis. Respir Care 58:e104–e106CrossRefPubMedGoogle Scholar
  9. 9.
    Kocyigit A, Gulcan Oksuz B, Yarar F, Uzun F, Igde M et al (2013) Hallucination development with montelukast in a child with asthma: case presentation. Iran J Allergy Asthma Immunol 12:397–399PubMedGoogle Scholar
  10. 10.
    Alkhuja S, Gazizov N, Alexander ME (2013) Sleeptalking! Sleepwalking! Side effects of montelukast. Case Rep Pulmonol 2013:813786Google Scholar
  11. 11.
    Minciullo PL, Saija A, Bonanno D, Feriazzo E, Gangemi S (2004) Montelukast-induced generalized urticaria. Ann Pharmacother 38:999–1001CrossRefPubMedGoogle Scholar
  12. 12.
    Jullaphant T, Nakpeng T, Srichana T (2018) Montelukast nasal spray: formulation development and in vitro evaluation. Pharm Dev Technol 27:1–10CrossRefGoogle Scholar
  13. 13.
    Jackson RT (1979) A new in vitro method of drug assay of nasal blood vessels. Arch Otorhinolarygol 225:33–38CrossRefGoogle Scholar
  14. 14.
    Jackson RT (1980) An in vitro technique for testing nasal vasodilating agent. Otolarygol Head Neck Surg 88:434–448CrossRefGoogle Scholar
  15. 15.
    Wang HW, Jackson RT (1988) Effects of lidocaine and procaine on canine nasal blood vessels. Ann Oto Rhinol laryngol 97:409–413CrossRefGoogle Scholar
  16. 16.
    Wang HW, Jackson RT (1988) Do cholinergic neurons directly innervate nasal blood vessels? Rhinology 26:139–146PubMedGoogle Scholar
  17. 17.
    Wang HW, Wang SW, Wang JY, Su. WY (1996) Effects of amphetamine on human nasal mucosa. Eur Arch Otorhinolaryngol 253:498–500PubMedGoogle Scholar
  18. 18.
    Fayyaz A, Khan JA, Ashraf MM et al (2017) Pharmacokinetic behavior of montelukast in indigenous healthy male volunteers. Park J Pharm Sci 30(6 suppl):2435–2439Google Scholar
  19. 19.
    Cobb DB, Abbott CL, Waston WA, Fernandez MC (2002) High-dose montelukast exposures in a 3-year-old and 5-year-old. Vet Hum Toxicol 44:91–92PubMedGoogle Scholar
  20. 20.
    Geller M, Melo LR, Coutinho SV (2000) Successful outcome of montelukast overdosage in an asthmatic child. Ann Allergy Asthma Immunol Mar 84:370CrossRefGoogle Scholar
  21. 21.
    Donald H, Arnold N, Bowan TF, Seger DL (2018) Adverse events are rare after single-dose montelukast exposures in children. Clin Toxicol 56:25–29CrossRefGoogle Scholar
  22. 22.
    Kao CH, Chu YH, Wang HW (2008) Effects of oxymetazoline on isolated rat’s tracheal smooth muscle. Eur Arch Otorhinolaryngol 265:695–698CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Otolaryngology-Head and Neck Surgery, Tri-Service General HospitalNational Defense Medical CenterTaipeiTaiwan, ROC
  2. 2.Graduate Institute of Clinical Medicine and Department of OtolaryngologyTaipei Medical University-Shuang Ho HospitalNew Taipei CityTaiwan, ROC
  3. 3.Department of PsychiatryFar Eastern Memorial HospitalNew Taipei CityTaiwan, ROC

Personalised recommendations